For product-related questions, orders or to set up a trial or demo, CONTACT US


Our Company

Allied BioScience is dedicated to developing innovative solutions to create cleaner human environments. We specialize in revolutionary, always-on antimicrobial coatings that provide continuous and long-lasting surface protection across public spaces. 

Our Mission

Our mission is to deliver eco-friendly, research-driven products and services, resulting in cleaner human environments. Our products are for use in a variety of industries, including healthcare, cleaning & sanitation, government & military, sports & fitness, mobile housing & facilities.

Our Memberships

Allied BioScience is a proud member of the following organizations.

– Association for Professionals in Infection Control & Epidemiology

– The Worldwide Cleaning Industry Association

Our History

Allied BioScience is a company with deep roots in basic environmental science. Since its inception, the primary goal of ABS is to find a way to develop surface coating technology to create a formulation that provides a long-lasting solution to maintain clean surfaces.

By 2008, the company had enlisted the help of some of America’s leading scientific minds in the fields of chemistry, biochemistry, microbiology and material sciences to help formulate a surface coating that today is known as SurfaceWise™, effective at inhibiting the growth of bacteria, fungi (mold and mildew) and algae which cause odor, staining and discoloration. These respected scientists include well-known experts in surface-coating technologies.

ABS is an allied team of scientists and business professionals dedicated to bringing a new technology that redefines what it means to have a clean environment.

Statement of Founder’s Secession

Craig Grossman
Chairman Emeritus, Allied BioScience

After many years of faithful service to Allied BioScience, Mr. Grossman stepped down from the board of directors on June 26, 2018, in order to focus on his other endeavors, including writing and entrepreneurial undertakings. Michael Ruley, CEO of ABS, said upon the change: “On behalf of our board of directors, the company’s management team and its shareholders, I’d like to thank Craig and his family for the many contributions he made as its founder and a member of the Allied BioScience Board. Craig’s vision was to develop long-lasting, antimicrobial coatings and solutions that ‘break the chain of infection,’ where the risk of harm to people is highest. Craig’s commitment and determination have left a lasting legacy at ABS.”

Craig can be reached with LinkedIn:

Insurance Advisory Board

Ken Fasola


Kenneth "Ken" Fasola is the President and Chief Executive Officer of HealthMarkets, Inc. He is a seasoned managed care executive and expert in distribution and business development. Prior to joining HealthMarkets, Ken was the CEO of UnitedHealthcare's Medicare business. He spent seven years at UnitedHealth Group and fourteen years at Humana. He is a graduate of The Pennsylvania State University and was named an Alumni Fellow in 2010.

Steve Shulman


Mr. Shulman serves as managing partner of Shulman Family Ventures, a private equity firm since 2008. In addition, Steve currently serves as the Chairman of the Board CareCentrix, Quartet, and serves as a director of VillageMD, MedImpact and Facet Technologies. Mr. Shulman has extensive experience in the healthcare industry, including serving as chief executive of several large healthcare sector organizations and as operating partner for a healthcare private equity firm, and his roles as a director of several privately held companies.

Jim Murray


Mr. Murray joined LifeCare in 2017 as the Chief Executive Officer, after a 28-year career with Humana where he served as Executive Vice President and Chief Operating Officer for various divisions. In this role, he was responsible for all business segments, service operations, and information technology functions. He was a member of the Executive Team, which set the strategic direction for the company. Prior to joining Humana, he served as a partner with the firm of Coopers & Lybrand, now PriceWaterhouseCoopers. Jim is a certified public accountant.

Mike McCallister


Mr. McCallister is retired Chairman of the Board and Chief Executive Officer, Humana Inc, where he served on the board over 13 years. Mike’s experience includes 39 years in the health care sector at Humana, Inc. combined with an intimate knowledge of operational, financial, and strategic development. Beyond Humana, Mr. McCallister plays a leadership role in key business advocacy organizations. He served on the board of the Business Roundtable and is the past chair of the organization’s Health and Retirement Task Force.

Peter Andruszkiewicz


Peter Andruszkiewicz (Peter A) is an accomplished healthcare executive with extensive leadership experience including roles as CEO and president of Blue Cross & Blue Shield of Rhode Island and president of Kaiser Foundation Health Plan of Georgia. He also served in executive positions at Blue Cross Blue Shield of the National Capital area (now CareFirst Blue Cross Blue Shield), and CIGNA Healthcare. He is currently an operating partner at Empactful Capital, a venture capital firm focused on early stage, tech enabled health care companies. Andruszkiewicz’s career has been dedicated to creating collaborative models in search of disruptive, positive change in the ways providers work together to deliver health care, the way care is financed, and enabling a new kind of engaged, activated healthcare consumer.

Scientific Advisory Board

Allied BioScience consults with some of the country’s leading scientific minds to deliver long-lasting solutions. Listed below are those distinguished scientists and academics currently serving on our scientific advisory board.

Charles P. Gerba, Ph.D.

Dr. Gerba is a professor in the Department of Soil, Water and Environmental Science at the University of Arizona. He conducts research on the transmission of pathogens through the environment. His recent research encompasses the transmission of pathogens by water, food and fomites (surface contamination); fate of pathogens in land-applied wastes; development of new disinfectants; domestic microbiology; and microbial risk assessment. He is the author of more than 500 articles and several books on environmental microbiology, risk assessment and pollution science. Dr. Gerba is a fellow of the American Academy of Microbiology, American Association for the Advancement of Science, and the International Water Association. Read more of Dr. Gerba’s publications on the US National Library of Medicine on

Daniel A. Moros, M.D.

Dr. Moros is associate clinical professor of neurology at Icahn School of Medicine at Mount Sinai in New York City. His specialization is in movement disorders and behavioral neurology. He has spent many years in the pharmaceutical industry as vice chairman and medical director of Taro Pharmaceutical Co. Ltd. with responsibilities for generic and new drug development and regulatory affairs. In addition to numerous publications in medical ethics and the philosophy of medicine, for the last two decades, Dr. Moros has co-taught a graduate course in medical ethics at the City University of New York and Icahn School of Medicine.

Timothy Wiemken, Ph.D.

Dr. Wiemken is an Associate Professor in the Saint Louis University Center for Health Outcomes Research. He previously served as Associate Professor at the University of Louisville School of Public Health and Information Sciences, Department of Epidemiology and Population Health and as Assistant Professor in the Division of Infectious Diseases. He earned his doctorate in Public Health from the University of Louisville, a Master’s Degree in Epidemiology from Saint Louis University, and has a Bachelor’s Degree in microbiology from Southern Illinois University. He was previously an infection preventionist at the University of Louisville Hospital, has been certified in infection prevention since 2008, and is a fellow of the Association for Professionals in Infection Control and Epidemiology (APIC). He is active with APIC and the Society for Healthcare Epidemiology of America (SHEA), serving on many national committees. Dr. Wiemken has authored and co-authored numerous guidelines and book chapters on infectious diseases and infection prevention, and over 125 peer-reviewed journal articles related to infectious disease epidemiology. His research interests include pneumonia, influenza, emerging respiratory pathogens, quality and patient safety, healthcare-associated infections, and machine learning/artificial intelligence in healthcare.

Ronald Wysocki Jr., Ph.D.

Dr. Wysocki serves as program director of chemistry and biochemistry at The Ohio State University and was the director of the Chemical Synthesis Facility in the Department of Chemistry at the University of Arizona. Formerly, he was chief scientist at Pharos Pharmaceuticals Inc. in Green Valley, Arizona; the senior chemist at Discovery Therapeutics Inc. in Richmond, Virginia; and the scientist and group leader for Whitby Research Inc. in Richmond, Virginia. Dr. Wysocki’s research areas include organic thin films, transmembrane proteins and various aspects of spectroscopy. He holds several U.S. patents in his area of research.


Allied BioScience is made up of a dedicated team of experienced professionals, all committed to helping our community stay cleaner.

Michael Ruley

Chief Executive Officer

Michael Ruley brings 30 years of expertise in business growth models as well as financial and tactical market positioning to advance the health mission of the company. Before joining Allied BioScience, Michael spent his career as a leader in the telecom industry. He has served as CEO of Airband Communications, Sparkplug Communications and Hawaiian Telcom. He also held posts as president and CEO of NextiraOne and several senior positions at XO Communications and Teleport Communications Group, and he currently serves as a board member of Tissue Genesis. Michael holds a Bachelor of Science in Business Administration and Management from the University of Kansas. Serving as a Board Member and CEO of three different North American-based companies, his expertise lies in quickly summing up a business – its strategy, model, financials, technology and competitive position – then outlining the right methods and building the right teams to accelerate top and bottom-line success. With a well-rounded blend of operating, financial, sales and marketing skills, Michael has successfully helped both private and publicly held entities strengthen and grow their valuations.

Maha El-Sayed, PhD

SVP, Science & Regulatory Affairs
Chief Science Officer

Maha El-Sayed is an experienced research and development executive. She received her MSc and PhD from MIT in Biophysical Chemistry, and she completed a post-doctoral at Stanford. Prior to joining Allied BioScience, Maha spent over 30 years in progressive leadership positions at The Clorox Company, a Fortune 500 Company, where she was devoted to developing and deploying both technologies and products, creating innovation strategies, and managing complex programs. She has hands on experience in leading and developing products based on complex chemistry and microbiology. Maha is a true pioneer, well-equipped to chart new territory for the Allied BioScience product portfolio.

Will Gerard

Chief Sales & Marketing Officer

Will is an experienced B2B Marketer with a proven track record of driving accelerated growth in both small, fast-paced environments and big, industry-leading companies spanning nearly two decades. Prior to joining Allied BioScience, Will played key leadership roles in driving double-digit sales growth annually for 10 years in The Clorox Company’s Professional Products Division, leading award-winning new product launches, integrated marketing campaigns and upstream new product innovation across EPA and FDA-regulated businesses in Healthcare and other Professional verticals. Will holds an Masters in Business Administration in Marketing from the Haas School of Business at the University of California at Berkeley and a Bachelor of Arts in Classics from Emory University.

Elias A. Shaheen, Ph.D., MBA

Vice President of Research

Dr. Shaheen recently retired from The Clorox Company where he served as a Research Director, Healthcare Division. At Clorox, he played a key role in developing and executing the environmental disinfection platform. He developed and managed extensive external network with leading academic experts that resulted in mutually beneficial and productive collaborations. Dr. Shaheen has a broad range of expertise in public health and environmental microbiology with more than 30 years of extensive experience with antimicrobial agents and disinfectants, infection control and prevention, open innovation and strategic planning. He holds 12 US patents in the area of environmental hygiene and disinfection and has published numerous peer-reviewed papers, abstracts, book chapters and technical papers. Prior to joining Clorox, Dr. Shaheen held positions with Yamanouchi Pharmaceutical, Pillsbury, ARCO Chemical, and University of Florida.

Board of Directors

Allied BioScience is governed by a distinguished board of directors who bring seasoned corporate experience and vision to ABS to assist in product development and business management. ABS’ board leverages this experience toward the common goal of creating best practices in breaking the chain of infection through the development of long-lasting antimicrobial technology.

Keith Tucker

Chairman of the Board

Keith is currently director and chairman of Century Bridge Capital, a real estate investment firm with offices in Dallas, Texas, and Beijing, China. He served as chairman and CEO of Waddell & Reed Financial Inc., a publicly held mutual fund complex (NYSE: WDR), bringing the firm’s assets under his management from $5 billion to more than $40 billion. Prior to this, Keith served as vice chairman of the board of Torchmark Corporation, a publicly held insurance, financial services and real estate development company (NYSE: TMK) and as a partner with KPMG Peat Marwick.

Hugh (Nick) Dallas

Nick has served as director of Environmental Service Professionals Inc. and holds a Branch II and III operator’s license from the California Structural Pest Control Board. He is a member of the Indoor Environmental Standards Organization and is a certified IESO trainer. He assists ABS with field operations.

Henry A. Crumpton

Ambassador Henry A. Crumpton is the founder and CEO of Crumpton Group (CG) LLC, a global strategy and business development firm. He is also the CEO of Crumpton Ventures, with investments in manufacturing, cyber-security, training/education, and robotics with an emphasis on unmanned aerial systems. He previously served on the advisory boards of AECOM, DC Capital Partners, and The Coca Cola Company. In addition to Allied BioScience, he currently is on the advisory board of Stone Canyon Industries.

A 24-year veteran of the CIA’s Clandestine Service, he is the recipient of the Distinguished Intelligence Medal — the CIA’s highest award for achievement. In 2005 President George W. Bush appointed him Ambassador-at-Large and US Coordinator for Counterterrorism. Ambassador Crumpton graduated from of the University of New Mexico and Johns Hopkins School of Advanced International Studies, with honors. He is the author of The New York Times bestseller, The Art of Intelligence

Charles A. Geoffrion

Charles joined Allied BioScience in 2008 as chief science officer after serving as associate vice president for research at the University of Arizona, as well as posts as the associate dean of science for corporate and external affairs and the campus research integrity officer. He is a member of the Pima County Board of Health and has experience in numerous public-private sector collaborations in America and internationally.

Vanessa Kerzner

Vanessa was in the hospitality industry for over a decade where she was an owner and board member of Kerzner International, a private company that built the Atlantis and One & Only hotels.  She is a graduate from Stanford University and INSEAD (France) and was a former consultant at Bain & Company in San Francisco and London.  During that time, she worked in M&A strategy and hospital cost reduction.  In addition to Allied BioScience, Vanessa currently serves on the board for a number of non-profit health care and education organizations, including Steadman Philippon Research Institute, Choate Rosemary Hall, a private high school in Connecticut, and the Butch Kerzner Memorial Trust Fund at the University of Johannesburg’s School of Tourism and Hospitality.

Daniel Moros, M.D.

Dr. Moros serves ABS as vice-chairman of scientific affairs. He is associate clinical professor of neurology at Icahn School of Medicine at Mount Sinai in New York City. His specialization is in movement disorders and behavioral neurology. He has spent many years in the pharmaceutical industry as vice chairman and medical director of Taro Pharmaceutical Co., Ltd. with responsibilities for generic and new drug development and regulatory affairs. In addition to being published in numerous publications in medical ethics and the philosophy of medicine, Dr. Moros has co-taught a graduate course in medical ethics at the City University of New York and Icahn School of Medicine for the last two decades.

George Peat

Vice-Chairman, International

George is a professional engineer (retired) with extensive experience in the refining and petrochemical sectors in the Far East, Europe and former Soviet Union. He served as vice president and general manager for a large engineering company in the Middle East. Peat sits on the University of British Columbia Chemical/Biological Engineering Industry Advisory Council, the advisory board of SG Biofuels, a developer of renewable biofuels in Latin and South America, and is on other for-profit and nonprofit boards. George has considerable experience with start-up companies. He serves as vice-chairman of international business development for ABS.

Dick Rothkopf

Dick brings over 45 years of experience in building successful, innovative companies. Prior to joining the board of Allied BioScience, Dick founded and cofounded a number of highly successful companies including Rothkopf Enterprises, Stand-buys, Learning Curve International and Ludorum. Dick also serves on a number of other corporate and not for profit boards and is a graduate of Cornell University.

Michael Ruley >>

Mohammed “Rab” Shanableh

With a career spanning 25 years in technology, Rab has held executive positions in Operations, Development and Systems Engineering leading divisions that have pioneered the way for the delivery of Mobile Packet Network. As co-founder and VP of Global Operations at Affirmed Networks (recently acquired by Microsoft), he shared in the coveted honor and success of Affirmed Networks being named a member of the prestigious Global Unicorn Club, an exclusive award recognizing outstanding current private companies valued at $1B+. He is presently the Managing Partner of Lydia Partners Venture Fund and the Co&#8209founder and CEO of OxeFit, a robotics tech company that focuses on robust strength training and human performance.